Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Navin Pandit

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Scientific Reports|July 4, 2023
Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship studyJung-Hoon Kim, Navin Pandit, Miyoun Yoo, et al.
Journal of Medicinal Chemistry|March 20, 2026
Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer TreatmentJi-In Kim, Ye-Hyun Kim, Navin Pandit, et al.
Bioorganic & Medicinal Chemistry|September 13, 2022
Discovery of BET specific bromodomain inhibitors with a novel scaffoldNavin Pandit, Miyoun Yoo, Tae Hyun Park, et al.
Frontiers in Oncology|April 15, 2022
PCW-1001, a Novel Pyrazole Derivative, Exerts Antitumor and Radio-Sensitizing Activities in Breast CancerMinsung Kang, Navin Pandit, Ah-Young Kim, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 26, 2024
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinomaYuna Kim, Kwan-Young Jung, Yun Hak Kim, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Scientific Reports|July 4, 2023
Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship studyJung-Hoon Kim, Navin Pandit, Miyoun Yoo, et al.
Journal of Medicinal Chemistry|March 20, 2026
Development of MKI-3: A Potent and Selective MASTL Inhibitor with Improved Efficacy for Cancer TreatmentJi-In Kim, Ye-Hyun Kim, Navin Pandit, et al.
Bioorganic & Medicinal Chemistry|September 13, 2022
Discovery of BET specific bromodomain inhibitors with a novel scaffoldNavin Pandit, Miyoun Yoo, Tae Hyun Park, et al.
Frontiers in Oncology|April 15, 2022
PCW-1001, a Novel Pyrazole Derivative, Exerts Antitumor and Radio-Sensitizing Activities in Breast CancerMinsung Kang, Navin Pandit, Ah-Young Kim, et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy|January 26, 2024
Inhibition of SIRT7 overcomes sorafenib acquired resistance by suppressing ERK1/2 phosphorylation via the DDX3X-mediated NLRP3 inflammasome in hepatocellular carcinomaYuna Kim, Kwan-Young Jung, Yun Hak Kim, et al.
Pageof 1